Akari Therapeutics (AKTX) Upgraded by ValuEngine to Sell

Akari Therapeutics (NASDAQ:AKTX) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Thursday.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics in a report on Sunday, September 17th. William Blair upgraded Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Finally, Canaccord Genuity restated a “buy” rating and set a $15.00 price objective on shares of Akari Therapeutics in a report on Friday, September 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $7.50.

Shares of Akari Therapeutics (NASDAQ AKTX) traded down $0.12 during trading on Thursday, hitting $4.86. The stock had a trading volume of 108,511 shares, compared to its average volume of 370,956. Akari Therapeutics has a 12-month low of $3.18 and a 12-month high of $22.20.

A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd grew its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 151,334 shares of the biopharmaceutical company’s stock after buying an additional 91,322 shares during the quarter. Hikari Power Ltd owned 1.28% of Akari Therapeutics worth $929,000 at the end of the most recent reporting period. Institutional investors own 21.06% of the company’s stock.

WARNING: “Akari Therapeutics (AKTX) Upgraded by ValuEngine to Sell” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/30/akari-therapeutics-aktx-upgraded-by-valuengine-to-sell.html.

About Akari Therapeutics

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply